KTTA Pasithea Therapeutics Corp.

0.4434USD-0.81%Mkt Cap: 14.82M $P/E: —

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…

HeadlineSourceTime
Older
New Strong Buy Stocks for July 20th

KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.

Zacks